Amplia Therapeutics Limited (ASX: ATX) has received approval from a second Human Research Ethics Committee (HREC) to conduct the company’s Phase 2 clinical trial of its Focal Adhesion Kinase (FAK) inhibitor, AMP945, in first-line patients with advanced pancreatic cancer.
The company recently announced (6 April 2022) that it received HREC approval to initiate the trial at sites in NSW, Australia.
As noted in that announcement, the company was awaiting the outcome of a second pending HREC application covering sites in Victoria, Australia.
This second approval has now been received, allowing the company to accelerate recruitment into the trial. No further HREC approvals are pending, and the company now adjusts its focus to the trial’s execution phase.
This second HREC approval will allow us to recruit patients more rapidly and begin to generate early efficacy and safety results in people with pancreatic cancer,” CEO and Managing Director, Dr John Lambert, said.
“Our focus is now on timely recruitment and execution of a high-quality trial that will support our future development plans for AMP945 in this very dangerous disease.”
